Ms Grainne Power:

Would that be in terms of these particular products or in general? With general clinical trial activity there is some activity within Europe. It is pretty much at the same level it was in 2017 when we completed our initial review. The areas of interest for those trials are chronic pain, psychiatric disorders and neurological conditions, including epilepsy. Many of those trials relate to products such as Sativex and also Epidiolex, in part. That is in the general context but in terms of the MCAP products themselves, the review of clinical data is not part of the assessment.